PDUFA target action date set to 10 June 2026 LUND, Sweden, Jan. 9, 2026 /PRNewswire/ -- Camurus (NASDAQ STO: CAMX) today announced that the U.S. Food and ...

MapLight Therapeutics, Inc. (MapLight) (Nasdaq: MPLT) today announced an update to the expected timing of topline results for its ongoing Phase ...

Introduction Each year, millions of people experience recurrent diverticulitis episodes. Elective sigmoid colon resection reduces the risk of recurrence, but The American Society of Colon and Rectal ...

The trial aims to establish clinical proof-of-concept in psoriasis and proof-of-mechanism for other CCR6- and Th17-associated autoimmune indicationsAllschwil, Switzerland - January 6, 2026 ...

A systematic review and meta-analysis of 15 studies found that ketogenic diets were associated with short-term reductions in ...

New analysis of a Phase 3 study of daridorexant shows that 50 mg improved both sleep and daytime functioning compared to placebo in women during ...

Idorsia receives approval from Health Canada for JERAYGO (aprocitentan) as the first and only endothelin receptor antagonist (ERA) for the treatment of resistant hypertension.JERAYGO is a new oral ant ...

Idorsia receives approval from Health Canada for JERAYGO™ (aprocitentan) as the first and only endothelin receptor antagonist ...

Objective Anxiety affects up to one-third of adults with asthma and is linked to poorer disease outcomes and reduced quality ...

Introduction Virtual reality-based telerehabilitation (VR-TR) combines gamified exercises with remote supervision for people with Parkinson’s disease (PD). Its effectiveness and safety in PD remain ...

Subscribe to Market Briefs for FREE and get daily investor updates: FREE Passive Income PDF Download it here: Recommended: ...

The FDA has approved Wegovy (semaglutide) tablets, the first oral GLP-1 receptor agonist for the treatment of obesity.